Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Madrigal Pharmaceuticals (MDGL) Other Gross PP&E Adjustments (2018 - 2025)

Madrigal Pharmaceuticals has reported Other Gross PP&E Adjustments over the past 13 years, most recently at -$26.9 million for Q4 2025.

  • Quarterly Other Gross PP&E Adjustments fell 43.41% to -$26.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.9 million through Dec 2025, down 43.41% year-over-year, with the annual reading at -$26.9 million for FY2025, 43.41% down from the prior year.
  • Other Gross PP&E Adjustments was -$26.9 million for Q4 2025 at Madrigal Pharmaceuticals, down from -$5.4 million in the prior quarter.
  • Over five years, Other Gross PP&E Adjustments peaked at -$411000.0 in Q2 2023 and troughed at -$35.7 million in Q4 2023.
  • The 5-year median for Other Gross PP&E Adjustments is -$1.7 million (2023), against an average of -$8.1 million.
  • Year-over-year, Other Gross PP&E Adjustments skyrocketed 61.12% in 2023 and then crashed 302.61% in 2025.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$25.1 million in 2021, then dropped by 10.73% to -$27.8 million in 2022, then decreased by 28.25% to -$35.7 million in 2023, then soared by 47.48% to -$18.7 million in 2024, then crashed by 43.41% to -$26.9 million in 2025.
  • Per Business Quant, the three most recent readings for MDGL's Other Gross PP&E Adjustments are -$26.9 million (Q4 2025), -$5.4 million (Q3 2025), and -$5.9 million (Q2 2025).